AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2260008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxyradiotherapy with a mixture of nitrogen and oxygen containing 8.0 to 8.5% O2, increased external irradiation doses by 40%
Number of subjects: 120
Study 2260008 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapeutic procedure
Number of subjects: 120
Study 31816508 — intervention group
Group type: EXPERIMENTAL
Intervention: Online social support groups
Number of subjects: 0
Study 29943097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor exercises
Number of subjects: 36
Study 29943097 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate strength training
Number of subjects: 36
Study 29943097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 26838252 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet intervention given to the intervention group of 280 participants.
Number of subjects: 500
Study 26838252 — intervention group
Group type: COMPARATOR
Intervention: Control group of 220 participants who did not receive the information leaflet.
Number of subjects: 500
Study 25166480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam (50 to 100 mg/d as needed)
Number of subjects: 28
Study 22940562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed opioid dose
Number of subjects: 198
Study 22940562 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported opioid dose
Number of subjects: 198
Study 22940562 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid deviation
Number of subjects: 198
Study 22940562 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers Questionnaire-II (BQ-II) scores
Number of subjects: 198
Study 22940562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence scores
Number of subjects: 198
Study 21073712 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual GP care plus facilitated physical activity
Number of subjects: 0
Study 21073712 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 0
Study 17953954 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing of the ovary (Group A)
Number of subjects: 32
Study 17953954 — intervention group
Group type: COMPARATOR
Intervention: Bipolar coagulation (Group B)
Number of subjects: 32
Study 17181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy group (DG: n 39) receiving approximately 1200 mg calcium/d and 7.5 microg vitamin D3/d through fortified dairy products
Number of subjects: 101
Study 17181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-supplemented group (CaG: n 26) provided with a calcium supplement of 600 mg/d
Number of subjects: 101
Study 17181890 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG: n 36)
Number of subjects: 101
Study 17181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy group (DG)
Number of subjects: 101
Study 14523483 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stent implantation and GP IIb/IIIa receptor inhibitors in patients with NSTEACS (group A)
Number of subjects: 479
Study 14523483 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) in patients with stable angina (group B)
Number of subjects: 479
Study 10813102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovelle (desogestrel 0.15 mg plus ethinyl estradiol 0.02 mg)
Number of subjects: 31
Study 10813102 — intervention group
Group type: EXPERIMENTAL
Intervention: Valette (dienogest 2.0 mg plus ethinyl estradiol 0.03 mg)
Number of subjects: 31
Study 10813102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovelle
Number of subjects: 31
Study 10813102 — intervention group
Group type: COMPARATOR
Intervention: Both contraceptives
Number of subjects: 31
Study 10813102 — intervention group
Group type: EXPERIMENTAL
Intervention: Valette
Number of subjects: 31
Study 8785183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetholone monotherapy
Number of subjects: 30
Study 8785183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetholone plus ketotifen
Number of subjects: 30
Study 8785183 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 30
Study 8785183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Oxymetholone monotherapy and Oxymetholone plus ketotifen)
Number of subjects: 30
Study 1830313 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (Lasix Retard)
Number of subjects: 24
Study 1830313 — intervention group
Group type: COMPARATOR
Intervention: Thiazide (hydrochlorthiazide)
Number of subjects: 24
Study 7091039 — intervention group
Group type: EXPERIMENTAL
Intervention: EG AA group, 3 eggs + 2 g ascorbic acid
Number of subjects: 40
Study 7091039 — intervention group
Group type: EXPERIMENTAL
Intervention: EGGS group, 3 eggs + placebo
Number of subjects: 40
Study 7091039 — intervention group
Group type: EXPERIMENTAL
Intervention: AA group, 2 g ascorbic acid
Number of subjects: 40
Study 7091039 — intervention group
Group type: COMPARATOR
Intervention: CONTROL group, placebo only
Number of subjects: 40
Study 31912490 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based couple therapy
Number of subjects: 3347
Study 31517749 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (PTT)
Number of subjects: 43
Study 31517749 — intervention group
Group type: COMPARATOR
Intervention: Conventional treadmill training (CTT)
Number of subjects: 43
Study 28928001 — intervention group
Group type: EXPERIMENTAL
Intervention: Drone-snowmobile Technique (DST)
Number of subjects: 20
Study 28928001 — intervention group
Group type: COMPARATOR
Intervention: Classical Line Search Technique (CLT)
Number of subjects: 20
Study 27669288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (6000 IU daily for 12 weeks)
Number of subjects: 20
Study 27669288 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement (for those with vitamin D status over 75 nmol/L)
Number of subjects: 20
Study 24731234 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 166
Study 24731234 — intervention group
Group type: COMPARATOR
Intervention: Group care (GC) treatment as usual (TAU)
Number of subjects: 166
Study 22092038 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (28 days)
Number of subjects: 0
Study 22092038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21115589 — intervention group
Group type: COMPARATOR
Intervention: B vitamins (5‐methyltetrahydrofolate 560 μg, vitamin B‐6 3 mg, vitamin B‐12 20 μg)
Number of subjects: 2501
Study 21115589 — intervention group
Group type: COMPARATOR
Intervention: Omega 3 fatty acids (600 mg of eicosapentanoic acid and docosahexaenoic acid at a ratio of 2:1)
Number of subjects: 2501
Study 18784373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (anti-IL-6 receptor antibody)
Number of subjects: 0
Study 16005273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin (sCT) 1.0 mg
Number of subjects: 152
Study 16005273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin (sCT) (0.15, 0.4, 1.0, or 2.5 mg)
Number of subjects: 152
Study 16005273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 12925107 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin + Cefepime
Number of subjects: 12
Study 12925107 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin + Amikacin
Number of subjects: 12
Study 12925107 — intervention group
Group type: COMPARATOR
Intervention: Cefepime alone
Number of subjects: 12
Study 12925107 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin alone
Number of subjects: 12
Study 12925107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime + Trovafloxacin
Number of subjects: 12
Study 10095141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml 50% sucrose solution
Number of subjects: 100
Study 10095141 — intervention group
Group type: COMPARATOR
Intervention: 2 ml sterile water (placebo)
Number of subjects: 100
Study 8608096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (60 mg)
Number of subjects: 1009
Study 8608096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1009
Study 1317687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (mean dose 35 mg qd)
Number of subjects: 21
Study 1317687 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (mean dose 54 mg bid)
Number of subjects: 21
Study 6485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0 to 120 min.)
Number of subjects: 20
Study 6485438 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0 to 120 min.) + GIH-CCK (1 IU/kg/h, 60 to 120 min.)
Number of subjects: 20
Study 6485438 — intervention group
Group type: COMPARATOR
Intervention: NaCl infusion (control)
Number of subjects: 20
Study 30267667 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated core postural control training with an unstable seat apparatus
Number of subjects: 33
Study 30267667 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy exercises (stretching and strengthening)
Number of subjects: 33
Study 30267667 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated core postural control training
Number of subjects: 33
Study 30879460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronator sparing plate osteosynthesis
Number of subjects: 60
Study 30879460 — intervention group
Group type: COMPARATOR
Intervention: Non-sparing approach
Number of subjects: 60
Study 30879460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26601738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 1307
Study 26601738 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 1307
Study 23104956 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 21
Study 23104956 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 21
Study 23157083 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of 0.75% ropivacaine (20 ml)
Number of subjects: 29
Study 23157083 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and flurbiprofen
Number of subjects: 29
Study 19592206 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (20,000 IU, 10 daily doses starting from the day of trauma)
Number of subjects: 79
Study 19592206 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 79
Study 19592206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 19017587 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of daily rifampin therapy
Number of subjects: 847
Study 19017587 — intervention group
Group type: COMPARATOR
Intervention: 9 months of daily isoniazid therapy
Number of subjects: 847
Study 15747247 — intervention group
Group type: EXPERIMENTAL
Intervention: 1x10(5) TCID(50) bPIV3 vaccine
Number of subjects: 192
Study 15747247 — intervention group
Group type: EXPERIMENTAL
Intervention: 1x10(6) TCID(50) bPIV3 vaccine
Number of subjects: 192
Study 15747247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 12451727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 1200 mg daily
Number of subjects: 80
Study 12451727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10600085 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary antimicrobial treatment team intervention
Number of subjects: 252
Study 10600085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study 7875277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic condenser humidifier
Number of subjects: 40
Study 7875277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protection system)
Number of subjects: 40
Study 3047886 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 14
Study 3047886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29305400 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation in amio-refractory patients
Number of subjects: 259
Study 29305400 — intervention group
Group type: COMPARATOR
Intervention: Escalated drug therapy in amio-refractory patients
Number of subjects: 259
Study 29305400 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation in sotalol-refractory patients
Number of subjects: 259
Study 29305400 — intervention group
Group type: COMPARATOR
Intervention: Escalated drug therapy in sotalol-refractory patients
Number of subjects: 259
Study 28083797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fludrocortisone
Number of subjects: 12
Study 28083797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone
Number of subjects: 12
Study 28083797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral fludrocortisone and intravenous hydrocortisone
Number of subjects: 12
Study 28083797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24929799 — intervention group
Group type: EXPERIMENTAL
Intervention: PHARMACOP-intervention
Number of subjects: 0
Study 24929799 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22245630 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 50 mg/day
Number of subjects: 51
Study 22245630 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg/day
Number of subjects: 51
Study 22245630 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg/day
Number of subjects: 51
Study 20186300 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training
Number of subjects: 14
Study 20186300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auditory training)
Number of subjects: 14
Study 18401693 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0
Study 15947502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel 2% with intracameral lidocaine 1%
Number of subjects: 39
Study 15947502 — intervention group
Group type: COMPARATOR
Intervention: Combined topical anesthesia (bupivacaine 0.5, oxybuprocaine, and diclofenac eyedrops) with intracameral lidocaine 1%
Number of subjects: 39
Study 12889589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral broad spectrum Ampicillin/Amoxicillin and Erythromycin therapy during conservative management of pPROM before 32 weeks' gestation
Number of subjects: 0
Study 10489079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring manipulation (experimenter said subject was physiologically calm and relaxed)
Number of subjects: 60
Study 10489079 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousing manipulation (experimenter said subject was physiologically aroused and nervous)
Number of subjects: 60
Study 10489079 — intervention group
Group type: COMPARATOR
Intervention: Control condition (experimenter remained silent)
Number of subjects: 60
Study 10489079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring manipulation
Number of subjects: 60
Study 10489079 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousing manipulation
Number of subjects: 60
Study 10489079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring manipulation vs Arousing manipulation
Number of subjects: 60
Study 8997659 — intervention group
Group type: EXPERIMENTAL
Intervention: Small particle size tetracycline in gel
Number of subjects: 31
Study 8997659 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle size tetracycline in gel
Number of subjects: 31
Study 1631985 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple CPAP with a 10 l latex balloon reservoir
Number of subjects: 10
Study 1631985 — intervention group
Group type: EXPERIMENTAL
Intervention: CR60 CPAP
Number of subjects: 10
Study 1631985 — intervention group
Group type: EXPERIMENTAL
Intervention: Down's CPAP
Number of subjects: 10
Study 1631985 — intervention group
Group type: COMPARATOR
Intervention: High-flow systems (CR60 CPAP and Down's CPAP)
Number of subjects: 10
Study 6490937 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers course
Number of subjects: 15
Study 6490937 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Advocates course
Number of subjects: 15
Study 6490937 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 31048579 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-high group
Number of subjects: 393
Study 31048579 — intervention group
Group type: COMPARATOR
Intervention: Microsatellite-stable subgroup
Number of subjects: 393
Study 29422181 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (four consecutive weekly 1-hour music classes)
Number of subjects: 48
Study 29422181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, maintained usual lifestyle habits)
Number of subjects: 48
Study 26787792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (0.25, 0.5, 0.75, 1.0, or 1.25 mg kg(‐1) i.v.)
Number of subjects: 99
Study 26787792 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (10, 25, 40, 55, or 70 µg kg(‐1) i.v.)
Number of subjects: 99
Study 26787792 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n=9)
Number of subjects: 99
Study 25488160 — intervention group
Group type: EXPERIMENTAL
Intervention: mini volume loading test (mVLT) in dehydrated subjects
Number of subjects: 12
Study 25488160 — intervention group
Group type: COMPARATOR
Intervention: mini volume loading test (mVLT) in hydrated subjects
Number of subjects: 12
Study 23141722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic inserts
Number of subjects: 30
Study 23141722 — intervention group
Group type: COMPARATOR
Intervention: Gracey curettes
Number of subjects: 30
Study 20816042 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg
Number of subjects: 60
Study 20816042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20816042 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 50 mg
Number of subjects: 60
Study 20816042 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 100 mg
Number of subjects: 60
Study 17432112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 0
Study 17432112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study 17432112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 17432112 — intervention group
Group type: EXPERIMENTAL
Intervention: LIP 394
Number of subjects: 0
Study 17432112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin or statins
Number of subjects: 0
Study 16087943 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (12 doses) followed by fluorouracil/doxorubicin/cyclophosphamide (FAC) every 3 weeks
Number of subjects: 258
Study 16087943 — intervention group
Group type: COMPARATOR
Intervention: Once every 3 weeks paclitaxel (4 cycles) followed by fluorouracil/doxorubicin/cyclophosphamide (FAC) every 3 weeks
Number of subjects: 258
Study 12461672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermentable carbohydrate (FC) intake
Number of subjects: 72
Study 12461672 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IDC)
Number of subjects: 72
Study 12461672 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy availability and requirement estimates
Number of subjects: 72
Study 11825402 — intervention group
Group type: EXPERIMENTAL
Intervention: Portacaval shunt with H‐grafts of 8 mm diameter with external ring reinforced (20 patients)
Number of subjects: 48
Study 11825402 — intervention group
Group type: COMPARATOR
Intervention: Side‐to‐side portacaval shunt (11 patients)
Number of subjects: 48
Study 11825402 — intervention group
Group type: COMPARATOR
Intervention: Proximal splenorenal shunt (17 patients)
Number of subjects: 48
Study 11825402 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 11825402 — intervention group
Group type: EXPERIMENTAL
Intervention: H-graft shunting (20 patients)
Number of subjects: 48
Study 11825402 — intervention group
Group type: EXPERIMENTAL
Intervention: H-graft shunting (19 survivals)
Number of subjects: 48
Study 8597010 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet manipulation to exclude foods that provoke symptoms
Number of subjects: 18
Study 8597010 — intervention group
Group type: COMPARATOR
Intervention: Control group (documenting but not altering food intake)
Number of subjects: 18
Study 1812628 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary balloon angioplasty
Number of subjects: 0
Study 1812628 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0
Study 6119249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 0
Study 6119249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine extra‐amniotic prostaglandin supplemented by curettage
Number of subjects: 0
Study 6119249 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30959546 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement surgery combined with partial fibula osteotomy (Group B)
Number of subjects: 17
Study 30959546 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic debridement surgery only (Group A)
Number of subjects: 17
Study 30215763 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole use
Number of subjects: 54113
Study 26427107 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoushen granule
Number of subjects: 156
Study 26427107 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 156
Study 24647391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic amino acid (AAA) supplementation (330 mg · kg(‐1) · d(‐1))
Number of subjects: 22
Study 24647391 — intervention group
Group type: COMPARATOR
Intervention: Ala (isonitrogenous control)
Number of subjects: 22
Study 22334767 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training program designed to improve activity of daily living (ADL) and physical capacity, lasting for 3 months.
Number of subjects: 98
Study 22334767 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 98